FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
New life sciences research from S. Ganguly and colleagues discussed
February 19th, 2009
According to recent research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, "Amount of drug actually reaching the target region in the lung following pulmonary inhalation is often estimated at less than 10% for older devices. Current particle and device engineering technologies have improved on this but Still fail to recover the ''wasted'' fraction of the drug and deliver it deeper into the lungs, which is generally desirable." "FDA has approved several exogenous surfactants for prophylaxis and rescue treatment of respiratory distress syndrome (RDS). Their approved mode of administration (intratracheal instillation) and site of action...
Source: FDA Law Weekly (2009-02-19)
|
